| Literature DB >> 28369286 |
Kirsti Uusi-Rasi1, Radhika Patil1, Saija Karinkanta1, Pekka Kannus1,2, Kari Tokola1, Christel Lamberg-Allardt3, Harri Sievänen1.
Abstract
BACKGROUND: Both exercise and vitamin D are recommended means to prevent falls among older adults, but their combined effects on fall-induced injuries are scarcely studied.Entities:
Keywords: Exercise; Injurious falls; Physical functioning; Vitamin D
Mesh:
Substances:
Year: 2017 PMID: 28369286 PMCID: PMC5861967 DOI: 10.1093/gerona/glx044
Source DB: PubMed Journal: J Gerontol A Biol Sci Med Sci ISSN: 1079-5006 Impact factor: 6.053
Figure 1.Trial profile.
Descriptive Group Characteristics (mean, SD) at the Baseline of the 2-Year Intervention (0 months)
| Characteristic | D−Ex− | D+Ex− | D−Ex+ | D+Ex+ |
|---|---|---|---|---|
| Age, years | 73.8 (3.1) | 74.1 (3.0) | 74.8 (2.9) | 74.1 (2.9) |
| Height, cm | 160.7 (5.4) | 159.2 (5.8) | 159.4 (6.1) | 159.7 (5.9) |
| Weight, kg | 72.0 (12.4) | 73.0 (13.1) | 70·9 (10·6) | 73·2 (10·5) |
| Fat, % | 41.1 (6.7) | 42.0 (7.2) | 41.3 (6.4) | 42.8 (5.3) |
| Calcium intake, mg/day | 1,040 (345) | 1,125 (420) | 1,119 (346) | 1,109 (385) |
| Vitamin D intake, µg/day | 10.2 (4.1) | 10.9 (4.2) | 10.3 (3.6) | 10.4 (3.9) |
| S-25(OH)D, nmol/L | 67.6 (18.8) | 65.8 (17.1) | 69.5 (18.0) | 65.5 (17.5) |
| Cognitive status, MMSE score (0–30)* | 28.5 (1.7) | 28.3 (1.4) | 28.2 (1.4) | 28.3 (1.5) |
| SPPB, range | 10.6 (3–12) | 10.7 (1–12) | 10.9 (7–12) | 10.8 (5–12) |
| ADL score (6–36)† | 6.7 (1.6) | 7.0 (2.2) | 6.8 (1.9) | 6.9 (1.8) |
| IADL score (8–48)† | 9.8 (2.7) | 10.7 (4.9) | 9.9 (3.8) | 10.3 (4.0) |
| Difficulties outdoor mobility, | 18 (17.6) | 19 (18.6) | 17 (16.5) | 17 (16.7) |
Notes: ADL = Activities of daily living; D−Ex− = placebo; D+Ex− =20 µg vitamin D daily; D−Ex+ = placebo + exercise; D−Ex+ = 20 µg vitamin D daily + exercise; MMSE = Mini Mental State Examination; IADL = Instrumental activities of daily living; SPPB = Short physical performance battery.
*Higher score indicates better functioning.
†Lower score indicates better functioning.
Rate of Falls per 100 Person-Years in Each Study Group During the 2-Year Follow-Up (24–48 months), and Incidence Rate Ratios (IRR) (95% CI) for Falls and Injurious Falls and Hazard Ratio (HR) (95% CI) For Fallers and Injured Fallers
| Outcome | D−Ex− | D+Ex− | D−Ex+ | D+Ex+ |
|---|---|---|---|---|
| Falls, all | 103.0 | 81.5 | 84.2 | 97.1 |
| Minor injurious falls | 29.4 | 20.1 | 20.0 | 24.3 |
| Medically attended injurious falls | 23.8 | 10.6 | 10.6 | 21.4 |
| Falls with fractures | 4.0 | 3.0 | 2.9 | 5.1 |
| IRR | ||||
| All falls | 1 | 0.78 (0.53–1.14) | 0.80 (0.55–1.18) | 0.88 (0.60–1.28) |
| Minor injurious falls | 1 | 0.66 (0.38–1.13) | 0.68 (0.39–1.16) | 0.79 (0.47–1.33) |
| Medically attended injurious falls | 1 | 0.45 (0.23–0.87) | 0.44 (0.23–0.86) | 0.84 (0.48–1.50) |
| HR | ||||
| All fallers | 1 | 0.86 (0.63–1.19) | 1.01 (0.74–1.39) | 0.99 (0.72–1.38) |
| Medically attended injured fallers | 1 | 0.62 (0.39–1.00) | 0.46 (0.28–0.76) | 0.55 (0.34–0.88) |
Note: D−Ex− = placebo; D+Ex− = 20 µg vitamin D daily; D−Ex+ = placebo + exercise; D+Ex+ = 20 µg vitamin D daily + exercise.
Baseline Values (SD) and Mean Changes (95% CI) Over Time in BMD and Physical Functioning in Each Study Group (The Rightmost Column, pb, Shows the Significance for Difference in Changes Compared with D−Ex−)
| Outcome | Absolute Baseline Value, Mean (SD) | Change at 24 Months, % |
| Change at 36 Months, % | Change at 48 Months, % |
|
|---|---|---|---|---|---|---|
| Femoral neck BMD, g/cm2 | ||||||
| D−Ex− | 0.872 (0.141) | −1.4 (−2.1 to −0.7) | −1.7 (−2.5 to −0.9) | −2.6 (−3.5 to −1.8) | ||
| D+Ex− | 0.821 (0.107) | −0.9 (−1.7 to −0.1) |
| −1.2 (−2.1 to −0.4) | −2.7 (−3.6 to −1.8) | .34 |
| D−Ex+ | 0.848 (0.115) | −1.1 (−1.8 to −0.4) |
| −1.9 (−2.7 to −1.1) | −2.1 (−3.1 to −1.3) | .93 |
| D+Ex+ | 0.875 (0.134) | −1.1 (−1.8 to −0.5) |
| −2.4 (−3.1 to −1.6) | −3.2 (−4.1 to −2.4) | .35 |
| Normal walking speed, m/s | ||||||
| D−Ex− | 1.04 (0.21) | −2.8 (−5.7 to 0.0) | −4.2 (−7.3 to −1.1) | −5.1 (−8.2 to −2.1) | ||
| D+Ex− | 1.00 (0.21) | −3.5 (−6.6 to −0.5) | .72 | −5.0 (−8.2 to −1.7 | −4.9 (−8.2 to −1.5) | .61 |
| D−Ex+ | 1.01 (0.19) | −1.8 (−4.8 to 1.2) |
| −0.7 (−3.9 to 2.6) | −0.5 (−3.7 to 2.8) | .11 |
| D+Ex+ | 1.03 (0.20) | −2.1 (−5.0 to 0.7) | .46 | −4.7 (−7.9 to −1.7) | −3.9 (−7.0 to −0.8) | .98 |
| Chair stand time, s | ||||||
| D−Ex− | 12.6 (2.4) | −0.8 (−4.2 to 2.7) | −1.7 (−5.3 to 1.9) | −0.7 (−4.6 to 3.3) | ||
| D+Ex− | 12.6 (3.3) | −4.5 (−8.0 to −0.9) | .46 | −3.3 (−6.9 to 0.4) | −3.9 (−8.0 to 0.2) | .58 |
| D−Ex+ | 12.5 (2.8) | −7.4 (−11.0 to −3.8) |
| −5.9 (−9.6 to −2.3) | −6.9 (−10.9 to −2.8) | .95 |
| D+Ex+ | 12.4 (2.5) | −7.7 (−11.2 to −4.3) | .054 | −5.5 (−9.1 to −1.9) | −5.2 (−9.2 to −1.2) | .19 |
| TUG time, s | ||||||
| D−Ex− | 9.31 (2.07) | −0.5 (−3.9 to 2.9) | 4.6 (1.2 to 8.0) | 8.7 (4.7 to 12.7) | ||
| D+Ex− | 9.73 (6.44) | 2.5 (−0.9 to 5.8) |
| 7.2 (3.9 to 10.5) | 7.4 (3.4 to 11.4) | .21 |
| D−Ex+ | 8.93 (1.94) | 1.9 (−1.7 to 5.5) | .19 | 4.4 (0.8 to 8.0) | 1.9 (−2.4 to 6.2) |
|
| D+Ex+ | 8.89 (1.64) | −1.4 (−4.9 to 2.1) | .63 | 4.3 (0.7 to 7.8) | 5.0 (0.8 to 9.2) | .62 |
| Muscle strength, N/kg | ||||||
| D−Ex− | 23.1 (6.1) | 1.4 (−3.2 to 6.1) | 0.6 (−4.2 to5.5) | 2.3 (−2.5 to 7.2) | ||
| D+Ex− | 23.4 (7.7) | 3.0 (−1.5 to 7.4) | .10 | 3.4 (−1.4 to 8.3) | 2.0 (−2.9 to 6.9) | .68 |
| D−Ex+ | 23.6 (6.0) | 16.7 (12.3 to 21.2) |
| 12.3 (7.7 to 16.9) | 10.2 (5.7 to 14.9) |
|
| D+Ex+ | 22.2 (6.6) | 17.3 (12.7 to 21.9) |
| 12.7 (7.9 to 17.5) | 12.4 (7.5 to 17.3) |
|
| Backwards walking, proportion of those able to do 6.1 m, % | At baseline | At 24 months | At 36 months | At 48 months | ||
| D−Ex− | 42.2 | 50.0 | 48.3 | 48.1 | ||
| D+Ex− | 30.4 | 40.5 | .68 | 43.9 | 45.9 | .34 |
| D−Ex+ | 45.1 | 72.7 |
| 65.9 | 61.7 |
|
| D+Ex+ | 51.0 | 78.0 |
| 71.6 | 73.8 |
|
Notes: D−Ex− = placebo; D+Ex− = 20 µg vitamin D daily; D−Ex+ = placebo + exercise; D+Ex+ = 20 µg vitamin D daily + exercise.
aBased on analysis of covariance (ANCOVA).
b p value for the overall group-wise difference from the end of intervention (24 months) to 48 months. Based on Generalized Linear Mixed Models (GLMM) or Linear Mixed Models (LMM).